Hanwha Group will invest US$300 million in OneWeb, a global space Internet company.Hanwha System announced on Aug. 12 that it will sign an investment contract with OneWeb and join its board of directors together with the British government, Bharti, one of the world's top three mobile carriers, E
Chong Kun Dang announced on July 5 that it has signed a contract with Oman’s pharmaceutical company Menagene Pharmaceutical Industries to export “Nesbel,” a second-generation biosimilar for anemia treatment.Menagene plans to sell Nesbel in six countries in the Middle East -- Oman, Saudi Arabia, the
Chong Kun Dang announced on Sept. 17 that it will export second-generation anemia biosimilar "Nesbell" to Lotus International, a company that is in charge of the Asian business of U.S. global pharmaceutical company Alvogen.Through the deal, Chong Kun Dang will supply Nesbell to Lotus and receive dow
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Dong-A ST delivered quarterly record-high earnings in 1Q20 on supply expansion prior to enforcement of the MFDS’s order to suspend business operations (March~May). But, operating losses in 2Q20 a
The author is an analyst of NH Investment & Securities. He can be reached at william.ku@nhqv.com. -- Ed. Dong-A ST’s 1Q20 earnings are expected to show y-y improvement, thanks to supply expansion prior to enforcement of the MFDS’s order to suspend business operations (March-May). However, we anticip
South Korea launched Cheollian 2A satellite in Guiana on Dec. 5 by using Arianespace’s Ariane 5 launch vehicle. South Korea had to pay 70 billion won (US$63 million) to 80 billion won (US$72 million) to the French company for launching the 3.5-ton satellite. Arianespace currently accounts for more t
Chong Kun Dang Pharmaceutical Corp. (CKD) announced on Dec. 2 that it has recently received sales approval for its second-generation anemia biosimilar ”CKD-11101" from the Ministry of Food and Drug Safety of South Korea. CKD-11101 is the first biosimilar version of novel erythropoiesis stimulating p
As the global biosimilar market keeps growing, Korean pharmaceutical companies that have been focusing on traditional drugs are turning their attention to biosimilars. Unlike the newly established large biosimilar companies, these companies follow a strategy to target Japan, which is a niche market,
Korea and New Zealand celebrated another year of growth, innovation and friendship under the theme of Korea-New Zealand “Inspire with Innovation” at a year-end networking function held at the Four Seasons Hotel Seoul on Wednesday, Nov. 15.The Year End Grand Hui, hosted by the New Zealand Chamber of
KT SAT announced a successful launch of Koreasat 7 in Guiana, France on May 5 (local time), which now allows KT SAT to have four communications satellites including Koreasat 5, Koreasat 6, and Koreasat 8 which is a condosat.Koreasat 7 is expected to reach its geostationary orbit on May 15 and begin
The number of approvals given to South Korean biosimilar clinical trials has surpassed that of multinational pharmaceutical companies.13 (in 10 items) out of the 25 biosimilar clinical trials (in 22 items) currently in progress are conducted by domestic companies. The number of approvals given clini